ReviewEuropean journal of nuclear medicine and molecular imaging2017
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Rapid assessment of target-binding fractions in molecular imaging agents using size-exclusion HPLC.EJNMMI radiopharmacy and chemistry · 2026Article
- MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways.NPJ precision oncology · 2025Article
- Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.Journal of clinical medicine · 2025Review
- Review
- Baseline and earlyCancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Calculation of alpha particle single-event spectra using a neural network.Frontiers in oncology · 2024Article
- Role of the Dietary Phytochemical Curcumin in Targeting Cancer Cell Signalling Pathways.Plants (Basel, Switzerland) · 2023Review
- Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment.Materials (Basel, Switzerland) · 2022Review
- Significant position of C-myc in colorectal cancer: a promising therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- The role ofEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.International journal of molecular sciences · 2022Review
- Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.International journal of molecular sciences · 2022Review
- Hybrid total-body pet scanners-current status and future perspectives.European journal of nuclear medicine and molecular imaging · 2022Review
- Mucin 1 as a Molecular Target of a Novel Diisoquinoline Derivative Combined with Anti-MUC1 Antibody in AGS Gastric Cancer Cells.Molecules (Basel, Switzerland) · 2021Article
- The Role of Curcumin in Cancer Treatment.Biomedicines · 2021Review
- Systematic imaging in medicine: a comprehensive review.European journal of nuclear medicine and molecular imaging · 2021Review
- Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[Molecular imaging and biology · 2021Article
- Gastrointestinal adverse events of immunotherapy.BJR open · 2021Review
- Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.Medicine · 2020Article
- Involvement of CHP2 in the Development of Non-Small Cell Lung Cancer and Patients' Poor Prognosis.Applied immunohistochemistry & molecular morphology : AIMM · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging continues to influence every aspect of cancer care including detection, diagnosis, staging and therapy response assessment. Recent advances in the understanding of cancer biology have prompted the introduction of new targeted therapy approaches. Precision medicine in oncology has led to rapid advances and novel approaches optimizing the use of imaging modalities in cancer care, research and development. This article focuses on the concept of targeted therapy in cancer and the challenges that exist for molecular imaging in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.